Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.79 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217172 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL888085 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29384615 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.94 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.90 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8672670 | 0.90 | ADORA3 (0.67) | ADORA1SMN1; SMN2 | |
| SCHEMBL20870832 | 0.90 | ADORA3 (0.67) | ADORA1SMN1; SMN2 | |
| SCHEMBL8621803 | 0.90 | ADORA3 (0.67) | ADORA1SMN1; SMN2 | |
| SCHEMBL30582997 | 0.90 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329077 | 0.90 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | BANK OF AMERICA, N.A. | 2025-09-04 | — | — | US | disclosed |
| US-20250270562-A1 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | BANK OF AMERICA, N.A. | 2025-08-28 | — | — | US | disclosed |
| US-20250257351-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12359201-B2 | 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-10125369-B2 | PCSK9 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180187198-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | BANK OF AMERICA, N.A. | 2018-07-05 | — | — | US | disclosed |
| EP-3336187-A1 | PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20170369872-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170362594-A1 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-12-21 | — | — | US | disclosed |
| US-20170304446-A1 | Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression | BANK OF AMERICA, N.A. | 2017-10-26 | — | — | US | disclosed |
| EP-2929031-B1 | PCSK9 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9783806-B2 | TMPRSS6 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160145629-A1 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-05-26 | — | — | US | disclosed |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | ADORA1 3419/4885DNPH1 4021/4885PRKAB2 119/4885 |
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | ADORA1 1034/4885DNPH1 4193/4885PRKAB2 463/4885 |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | PCSK9, LDLR, RNASE1 | ADORA1 3722/4885DNPH1 3890/4885PRKAB2 1359/4885 |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | ADORA1 3722/4885DNPH1 3890/4885PRKAB2 1359/4885 |
| US-20170362594-A1 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TMPRSS6, RNASE1, TFRC | ADORA1 3585/4885DNPH1 3817/4885PRKAB2 2129/4885 |
| US-20170304446-A1 | Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression | HAO1, HAO2, ACOX1 | ADORA1 1080/4885DNPH1 1413/4885PRKAB2 3932/4885 |
| US-10125369-B2 | PCSK9 iRNA compositions and methods of use thereof | PCSK9, LDLR, RNASE1 | ADORA1 3722/4885DNPH1 3890/4885PRKAB2 1359/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | ADORA1 1543/4885DNPH1 3312/4885PRKAB2 1805/4885 |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | ADORA1 4357/4885DNPH1 3608/4885PRKAB2 1442/4885 |
| US-20180187198-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | ADORA1 4357/4885DNPH1 3608/4885PRKAB2 1442/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | ADORA1 1114/4885DNPH1 3183/4885PRKAB2 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.